+66 0(9) 2192 7555



Dr. Kampon is an internationally recognized Thai pharmacologist who is currently involved in stem cell technology in Thailand.

Dr. Kampon was an Associate Professor in the Department of Pharmacology at Mahidol University, Thailand's premier teaching institution in medicine. He was a consultant to the Thai Food and Drug Administration, and a member of several Subcommittees appointed by the Ministry of Public Health. He is also Adjunct Scholar at the Center for the Study of Drug Development at Tufts University in Boston.

Dr. Kampon received a Bachelor's degree in medical science in 1972, a Doctor of Medicine degree in 1974, and a Ph.D. in pharmacology in 1978 from Mahidol University. He became a medical scholar and professor at the university and was appointed in 1984 as Chairman of the Department of Pharmacology and Director of the Toxicology Graduate Program - posts he held until 1988. Subsequent appointments at the university have included Deputy Dean of the Faculty of Graduate Studies (1988-1989 and 1992-1995), Assistant to the President on Foreign Relations and Research (1989-1990), and Vice-President on Research and Foreign Relations (1990-1991).

During his academic career, Dr. Kampon gained international recognition as a drug-development specialist through his scientific publications and research appointments in British and U.S. universities. He has been a British Council Research Fellow in pharmacology at the University of Leicester (1978-1979) and a British Council Visiting Scientist in clinical pharmacology at the University of Edinburgh (1987-1988), and received a cancer study grant from the Royal Marsden Hospital in Sutton, England (1988-1989). He also has been a Merck International Fellow in clinical pharmacology at University of Rochester in the United States (1981-1982).

Dr. Kampon is a member of the Medical Association of Thailand, the Pharmacological and Therapeutic Society of Thailand, and the Toxicological Society of Thailand. His areas of expertise include obesity and metabolic syndrome, complementary medicine and stem cell therapy. At present he is actively engaged in stem cell treatment derived from hematopoietic, adipose tissue and baby tooth stem cells. He has the extensive collaboration with leading Institute in U.S.A., Germany, Switzerland, Ukraine, Russia, Korea and China. He aims to bring Thailand to be the leading medical hub of Asia having stem cell technology as the key technology.